•
-
Biomanufacturing
Bioconvergence for Biomanufacturing: Closing the Scale Gap in Synthetic Biology
Synthetic biology has entered a new era of capability. AI-driven protein design, advanced cell engineering, and increasingly automated labs are rapidly expanding what is scientifically possible. Yet commercial scale and sustainable economics remain out of reach. The core challenge is no longer whether biology can be engineered, but whether it can be consistently deployed in real-world environments. Moving from lab success to industrial production introduces a new set of constraints, from process robustness and yield to infrastructure, supply chains, and cost. This session focuses on what it actually takes to translate innovation into manufacturing reality. Rather than diagnosing failure points, it highlights the systems, platforms, and partnerships that enable biology to scale. What is working today, where are the key integration bottlenecks, and how do we build a more cohesive path from design to deployment?
•
-
Biomanufacturing
Bioconvergence for Biomanufacturing: Closing the Scale Gap in Synthetic Biology
Synthetic biology has entered a new era of capability. AI-driven protein design, advanced cell engineering, and increasingly automated labs are rapidly expanding what is scientifically possible. Yet commercial scale and sustainable economics remain out of reach. The core challenge is no longer whether biology can be engineered, but whether it can be consistently deployed in real-world environments. Moving from lab success to industrial production introduces a new set of constraints, from process robustness and yield to infrastructure, supply chains, and cost. This session focuses on what it actually takes to translate innovation into manufacturing reality. Rather than diagnosing failure points, it highlights the systems, platforms, and partnerships that enable biology to scale. What is working today, where are the key integration bottlenecks, and how do we build a more cohesive path from design to deployment?
SynBioBeta is where the people building with biology meet the people funding, buying, and partnering with them. If you're raising capital, scouting the next wave of AIxBIO companies, or looking for your next technology partner - the people you need are here for three days.
The startups on stage this year are building programmable RNA medicines, virtual cell models, AI-designed enzymes, and proteins that replace sugar - alongside GSK, Sanofi, Novo Nordisk, Eli Lilly, J&J, Mars, Apple, Google, NVIDIA, Unilever, and P&G.
Watching where the partnerships form and which technologies the biggest players are actually evaluating is something you can't get from a report or a webinar. And our 1:1 Partnering App lets you book meetings before you arrive.
“SynBioBeta is a who’s who of AI and biology.
This is where the future is being built, so don't miss it”
“SynBioBeta is a who’s who of AI and biology.
This is where the future is being built, so don't miss it”
Eric Schmidt
Former CEO
"For every single fund at Boom Capital, one of our best companies has come directly from SynBioBeta. I met Mammoth Bio at SynBioBeta, and I met Nabla Bio at SynBioBeta."
Celestine Schnugg
Founder
"Nabla was accelerated into existence because of SynBioBeta. I met Seth Bannon from 50 Years, Cee Cee Schnugg from Boom Capital, and others from Y Combinator there, and those same people seeded Nabla. The vibe, leverage, and energy at SynBioBeta are unreal."
"Nabla was accelerated into existence because of SynBioBeta. I met Seth Bannon from 50 Years, Cee Cee Schnugg from Boom Capital, and others from Y Combinator there, and those same people seeded Nabla. The vibe, leverage, and energy at SynBioBeta are unreal."
Surge Biswas
Founder
"Our Series A came together because of a little bit of SynBioBeta magic. I’ve been attending for a decade and it’s been inspiring to watch the field evolve from a lot of hopes and dreams to real products and applications."
"Our Series A came together because of a little bit of SynBioBeta magic. I’ve been attending for a decade and it’s been inspiring to watch the field evolve from a lot of hopes and dreams to real products and applications."
Jacob Glanville
Founder & CEO
"I met Algen at SynBioBeta and later invested in the company. It’s exactly the kind of connection that makes the community so valuable."
"I met Algen at SynBioBeta and later invested in the company. It’s exactly the kind of connection that makes the community so valuable."
Bill Tai
Co-founder
"At SynBioBeta I met the team at Biomatter, an AI-driven enzyme design company. The environment made it easy to start a real conversation. That conversation turned into a collaboration to improve one of our enzymes. We're now exploring entirely new performance possibilities together."
"At SynBioBeta I met the team at Biomatter, an AI-driven enzyme design company. The environment made it easy to start a real conversation. That conversation turned into a collaboration to improve one of our enzymes. We're now exploring entirely new performance possibilities together."
Luis Cascao-Pereira
Head of Digital Biology
"Every time I attend SynBioBeta, I walk away with something transformative – a new investor, a fantastic hire, or an idea that changes how we work. It’s a community unlike any other."
"Every time I attend SynBioBeta, I walk away with something transformative – a new investor, a fantastic hire, or an idea that changes how we work. It’s a community unlike any other."
Ola Wlodek
CEO
